• Article highlight
  • Article tables
  • Article images

Article History

Received : 15-10-2024

Accepted : 21-11-2024



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 69

PDF Downloaded: 28


Get Permission Rathore, Saklain, Rayyan, Kumar, Jaiswal, and Godke: Quantitative estimation & validation of paracetamol and lornoxicam by using hydrotropy solubilization phenomena


Introduction

To improve the aqueous solubility of medications that are not very soluble in water, a variety of methods have been used. One such technique is hydrotropic solubilisation.1 A class of chemical compounds known as hydrotropes increases the aqueous solubility of some solutes that are normally sparingly soluble in water by a factor of several. The important components of a drug's therapeutic efficacy are its bioavailability and, ultimately, its solubility to achieve the right concentration in the systemic circulation. Because of their limited water solubility and high permeability, dissolution from delivery methods is the rate-limiting step in their absorption and systemic bioavailability.2, 3 Because of the ease of recovering the dissolved solute and the potential for reusing hydrotrope solutions, hydrotropy can be viewed as a promising and industrially appealing technology for increasing the water solubility of intractable and marginally soluble pharmaceuticals. To improve the aqueous solubility of medications that are not very soluble in water, hydrotropes like PEG 6000, sodium salicylate, sodium benzoate, sodium hydroxide, niacinamide, sodium citrate, urea and polyvinyl alcohol, have been used.3 Chemically known as N-(4-hydroxyphenyl) acetamide, or PCM (Figure 1 a), PCM has antipyretic and analgesic properties and is applied to alleviate pain such headaches, toothaches, rheumatism, and neuralgia.4 The way that PCM works is by inhibiting the COX enzyme and prostaglandin synthesis in the CNS5 and by directly affecting the hypothalamus, which regulates body temperature.6 As a novel (NSAID) with notable analgesic characteristics, LOX is chemically known as 6-chloro-4-hydroxy-2-methyl- N-2-pyridyl-2H-thieno [2, 3-e]-1, 2-thiazine-3-carbox-amide-1, 1-dioxide) (Figure 1 b).7 The yellow crystalline material known as LOX has a partition coefficient of 1.8 and a pKa of 4.7 when measured in phosphate pH 7.4-octanol.Spectrophotometric methods8, 9, HPLC 10, TLC11, HPTLC 12, LC-MS 13, FTIR14, amperometric analysis15, fluorimetry 16, and micellar electrokinetic chromatographic method17 have all been reported to estimate PCM alone or in combination with other medications. There aren't many analytical techniques for voltametric LOX determination.18 UV spectrophotometric19, polarographic.20 There have been reports of LC/MS/MS21, 22 and HPLC23, 24, 25, 26 in pharmaceutical formulations and plasma. However, no techniques for spectrophotometric assessment of the dose form of paracetamol and lornoxicam tablets employing hydrotropic solubilising agents have been published.

Figure 1

Chemical structure of (A) PCM and (B) LOX

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/9035c16f-5bfd-47f0-aab4-5dabffbc534bimage1.png

Materials and Methods

Materials

A UV/visible spectrophotometer (Model-UV-1700, Shimadzu, Japan) was utilized to measure the spectrum. This has a 1 cm quartz matched cell and a double beam double detector arrangement. Wensar Ltd. sold the electronic balance, REMI Instruments Limited sold the cyclo mixer, and REMI Instruments Limited sold the centrifuge. Lupin Laboratories, located in Mumbai, India, generously provided an analytically pure sample of PCM and LOX. Mumbai-based Loba Chemie Pvt. Ltd. provided the urea. The pharmacological dosage forms used in this study were Neucam-P (Lupin (Maxter) Laboratories, Mumbai, India) and Lornicam Plus 8 (Aristo pharmacological Pvt. Ltd, Delhi, India) tablets, which included 500 mg PCM and 8 mg LOX. They were bought from the neighbourhood drugstore. In-house triple-distilled water was produced.

Method 1- Simultaneous estimation method

Determination of λmaxof drugs

Pure LOX and PCM (10 mg/ml) were combined to create a standard solution. A UV spectrophotometer was used to scan the pure drug solutions, and the maximum absorbance for LOX and PCM was found to be 384.0 nm and 244.0 nm, respectively. Figures two and three display the UV spectra.

Standard stock solution

A carefully weighed powder sample containing 100 mg of PCM and LOX was added to a 100 ml volumetric flask separately along with 20ml of an 8M urea solution. The drug was dissolved in the flask by sonicating it for around 20 minutes in order to get a concentration of 1000μg/ml. After that, distilled water was used to regulate the volume. The mixture was filtered with Whatmann filter paper No. 41.

Working standard solution

One milliliter of the LOX standard stock solution was transferred to a 100 milliliter volumetric flask, and distilled water was used to adjust the volume. Absorbance was evaluated in a UV spectrophotometer following the generation of different amounts, ranging from 2 to 10μg/ml. One milliliter of the PCM standard stock solution was added to a 100 milliliter volumetric flask, and the volume was adjusted with distilled water. A UV spectrophotometer was used to evaluate absorbance at various doses (20 to 60μg/ml).

Preparation of the calibration curves of the drug

Three absorbance measurements of both reference drug solutions were made, and plotting the mean drug absorbance against the drug's concentration was done for PCM and LOX, respectively. The regression equation was found using this curve. Table 1 shows the LOX and PCM optical parameter results.Figure 4, Figure 5 depict a typical calibration curve for PCM and LOX, respectively.

Preparation of analysis of tablet formulation

To create a fine powder, twenty tablets were precisely weighed and crushed. To solubilise the medication, 20 ml of 8M urea solution and 100 mg of carefully weighed paracetamol were added to a 100 ml volumetric flask. After that, the flask was shaken for around ten minutes. The volume was adjusted using distilled water, which was subsequently filtered. A 10-milliliter volumetric flask with 10 milliliters of filtrate was filled with five milliliters of solution, and the volume was corrected to 10 milliliters using distilled water. The volume was changed to achieve the desired final concentration. At 244.0 and 384.0 nanometers the absorbance was measured in relation to a blank.Table 2 displays the findings of the tablet formulation investigation.

Validation

Linearity

Linearity is the ability of an analytical method to yield tests that are exactly proportionate to the analyte's absorbance in the sample (within a given range). The calibration curve was created after five different concentrations (range from 2 to 10 μg/ml and 20 to 60 μg/ml) were examined. Each concentration's absorbance was measured three times, and the mean absorbance for PCM and LOX was calculated, respectively.Figure 4, Figure 5 shows the regression equation and correlation coefficient of the drug's standard curve for PCM and LOX, respectively.

Accuracy

Recovery tests were carried out to verify the established approach's accuracy. To the pre-analyzed sample solution, a certain concentration of the standard drug (80%, 100%, and 120%) was added. After that, the recovery was analyzed, andTable 3 shows the findings.

Precision

Repeatability

Standard dilutions were prepared and three replicates of each dilution were analyzed on the same day to guarantee repeatability. After then, the data were statistically assessed. Standard dilutions were prepared, and on different days, multiple analysts analyzed three duplicates of each dilution.Table 4 presents the findings of a statistical analysis.

Intermediate precision

Analyst to analyst

The standard dilution was made, and for every developed procedure, three copies of each dilution were examined by several analysts. The findings, which show the intermediate precision with differences within laboratories (various days, different analyzers, different equipment, etc.), are shown in Table 5.

Absorbance ratio method (Q-Analysis)

The Q-absorbance method uses the ratio of absorbance at two specified wavelengths, one of which represents the isoabsorptive point and the other the λmax of one of the two components. As outlined in method 1, the calibration curve and standard stock solution were created. Two wavelengths were chosen from the overlain spectra of LOX (10μg/ml) and PCM (20μg/ml) to construct the Q-absorbance depicted in Figure 6: the isoabsorptive point at 279.0 nm and the LOX λmax at 384.0 nm. The absorptivity coefficients of each medication at both wavelengths were ascertained, along with the absorbances of PCM at 279.0 nm (isoabsorptive point) and LOX at 384.0 nm (λmax).Table 6 displays the findings of the tablet formulation investigation.

Validation

Linearity

After analysis, five different concentrations (range from 2 to 10μg/ml and 20 to 60μg/ml) were plotted on the calibration curve. For every concentration, absorbances were measured three times, and the mean absorbance for PCM and LOX was calculated, respectively.Figure 4, Figure 5 show the regression equation, correlation coefficient and standard curve for PCM and LOX, respectively.

Accuracy

To the pre-analyzed sample solution, a certain concentration of the standard drug (80%, 100%, and 120%) was added. After that, the recovery was analyzed, and Table 7 shows the findings.

Precision

Repeatability

After then, the data were statistically assessed. Standard dilutions were prepared, and on different days, multiple analysts analyzed three duplicates of each dilution.Table 8 presents the findings of a statistical analysis.

Analyst to analyst

Three replicates of the standard dilutions were prepared for each of the suggested processes, and the outcomes are shown inTable 9.

Figure 2

Selection of λmax of Lornoxicam

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/9035c16f-5bfd-47f0-aab4-5dabffbc534bimage2.png
Figure 3

Selection of λmax of paracetamol

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/9035c16f-5bfd-47f0-aab4-5dabffbc534bimage3.png
Figure 4

Standard calibration curve of lornoxicam

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/9035c16f-5bfd-47f0-aab4-5dabffbc534bimage4.png
Figure 5

Standard calibration curve of paracetamol

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/9035c16f-5bfd-47f0-aab4-5dabffbc534bimage5.png
Figure 6

Overlay spectra of lornoxicam and paracetamol

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/9035c16f-5bfd-47f0-aab4-5dabffbc534bimage6.png
Table 1

Lornoxicam and paracetamol optical parameter results

S. No.

Parameter

Lox

Pcm

1.

λmax

384nm

244 nm

2.

(µg/ml)

2-10µg/ml

20-60µg/ml

3.

Regression equation

Y=0.104 conc.+0.0108

Y=0.0211conc.-0.0039

4.

Correlation Coefficient(r2)

0.999

0.999

Table 2

Method 1: Assay of lornoxicam and paracetamol in tablet formulation

BrandName

PCM

LOX

LabelClaim(mg)

%Purity

Label Claim(mg)

%Purity*

Neucam-P

500

99.5%

8

98.8%

Table 3

Recovery studies to assess formulation accuracy (method 1)

Drug

Amountpresent (μg/ml)

Amountadded (μg/ml)

Amountfound (μg/ml)

% Recovery

PCM

25

20

19.8

99.0

25

25

25.1

100.4

25

30

29.9

99.6

LOX

6

4.8

4.79

99.7

6

6

5.99

99.8

6

7.2

7.22

100.2

Table 4

Findings from the tablet formulation analysis data (Repeatability)

Drug

Labelclaim mg/tab

Amount found* mg/tab

Labelclaim (%)

S.D.

% RSD

PCM

500

498.99

99.79

0.107

0.115

LOX

8

7.98

99.75

0.115

0.115

Table 5

The outcome of technique 1's analyst-to-analyst precision

Analyst

Labelclaim mg/tab

Amountfound* mg/tab

Labelclaim (%)

S. D.

%RSD

PCM

LOX

PCM

LOX

PCM

LOX

PCM

LOX

PCM

LOX

1

500

8

500.10

7.93

100.02

99.12

0.264

0.150

0.132

0.154

2

500

8

498.00

7.90

99.60

98.75

0.159

0.120

0.107

0.135

Table 6

Method 2: assay of lornoxicam and paracetamol in tablet formulation

BrandName

PCM

LOX

LabelClaim(mg)

%Purity

LabelClaim(mg)

%Purity*

Lornicam plus 8

500

99.80

8

98.70

Table 7

Recovery studies to assess formulation accuracy (method 2)

Drug

Amountpresent (μg/ml)

Amountadded (μg/ml)

Amountfound (μg/ml)

%Recovery

PCM

25

20

20.1

100.50

25

25

25.3

101.20

25

30

30.0

100.00

LOX

6

4.8

4.82

100.41

6

6

5.95

99.16

6

7.2

7.16

99.44

Table 8

Findings from the analysis repeatability of tablet formulation data (method 2)

Drug

Labelclaim mg/tab

Amountfound* mg/tab

Labelclaim (%)

S.D.

%RSD

PCM

500

498.50

99.70

0.712

0.714

LOX

8

7.92

99.00

0.251

0.258

Table 9

The outcome of technique 2's analyst-to-analyst precision

Analyst

Labelclaim mg/tab

Amount found*mg/tab

Labelclaim (%)

S.D.

%RSD

PCM

LOX

PCM

LOX

PCM

LOX

PCM

LOX

PCM

LOX

1

500

8

500.20

7.98

100.04

99.75

0.156

0.198

0.214

0.207

2

500

8

499.50

7.97

99.90

99.62

0.075

0.101

0.284

0.265

Conclusion

Because the 8M urea solution (as a hydrotropic agent) did not interfere, the simultaneous equation method and the absorbance ratio method were found to be simple, accurate, economical, and rapid for the measurement of PCM and LOX in bulk and dosing forms for tablets. The recommended method works well for routinely examining dose forms that contain LOX and PCM.

Source of Funding

None.

Conflict of Interest

None.

References

1 

AS Shete AV Yadav AP Dabke SS Sakhare Formulation and evaluation of hydrotropic solubilization based suspensions of GriseofulvinInt J Pharma Sci Res201011517

2 

SNA Vinnakota R Deveswaran S Bharath BV Basavaraj Application of mixed hydrotropic solubilization in spectrophotometric estimation of aceclofenac in tabletsJ Curr Pharm Res2011132236

3 

V Gurumurthy R Deveswaran S Bharath BV Basavaraj V Madhavan Application of hydrotropic solubilisation in simultaneous estimation of Atenolol and Amlodipine BesylateAsian J Res Chem2012515760

4 

SNJ Budavari The Merck Index. 12thMerck Research Lab., Division of Merck and Co. Inc199619

5 

P Amadio Peripherally acting analgesicsAm J Med1984773A1726

6 

C Dollery Therapeutic Drugs2ndChurchill Livingstone1999119

7 

JA Balfour A Fitt LB Barradell A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditionsDrugs199651463957

8 

M Nogowska I Muszalska M Zajac Simultaneous spectrophotometric determination of acetyl salicylic acid, paracetamol and caffeine in pharmaceutical preparationsAnal Chem19994410419

9 

E Dinc C Yucesoy F Onur Simultaneous spectrophotometric determination of mefenamic acid and paracetamol in pharmaceutical preparations using ratio spectra derivative spectrophotometry and chemometric methodsJ Pharm Biomed Anal20022861091100

10 

SS Zarapkar UP Hulkar NP Bhandari Reverse phase HPLC determination of ibuprofen, paracetamol and methocarbamol in tabletsIndian Drugs1999367103

11 

YR Liang J Hu HL Wu LY Le WJ Wang Determination of paracetamol and amantadine HCl tablets in pharmaceuticals by HPLCTLC and CRM. Yaowu Fenxi Zazhi (Chinese)2006264115

12 

AP Argekar JG Sawant Simultaneous determination of paracetamol and mefenamic acid in tablets by HPTLCJ Planar Chromatogr-Mod TLC1999123615

13 

M Godejohann LH Tseng U Braumann J Fuchser M Spraul Characterization of paracetamol metabolite using on-line LCSPE- NMR-MS and a Cryogenic NMR-ProbeJ Chromatogr A200410581-21917

14 

S Ekgasit NP Ayakkorn D Tongsakul C Thammancharoen T Kongyou A novel ATR FTIR micro spectroscopy technique for surface contamination analysis without interference of substrateAnal Sci200723786371

15 

SJ Prabakar SS Narayanan Amperometric determination of paracetamol by a surface modifi ed cobalt hexacyanoferrate graphite wax composite electrodeTalanta2007725181845

16 

EJ Llorent-Martínez D Satinsky P Solich P Orega-Barrales AM Diaz Fluorimetric SIA optosensing in pharmaceutical analysis determination of paracetamolJ Pharm Biomed Anal200745231839

17 

D Emre N Ozaltin Simultaneous determination of paracetamol, caff eine and propyphenazone in ternary mixtures by micellar electro kinetic capillary chromatographyJ Chromatogr B2007847212658

18 

MM Ghoneim AM Beltagi A Radi Square-wave adsorptive stripping voltammetric determination of the anti-inflammatory drug lornoxicamAnal Sci20021821839

19 

E Nemutlu S Demircan S Kir Determination of lornoxicam in pharmaceutical preparations by zero and fi rst order derivative UV Spectrophotometric methodsPharmazie20056064216

20 

C Ibrahim K Nisa A Sule Polarographic determination of lornoxicam in pharmaceutical formulationsCBU J Sci200951119

21 

Y H Kim H Y Ji E S Park S W Chae H S Lee Liquid chromatography electrospray ionization tandem mass spectrometric determination of lornoxicam in human plasmaArch Pharm Res200730905915

22 

YL Zeng XY Chen YF Zhang DF Zhong Determination of lornoxicam in human plasma by LC/MS/MSYao Xue Xue Bao20043921327

23 

SR Welte D Rich Determination of the novel nonsteroidal anti-inflammatory drug lornoxicam and its main metabolite in plasma and synovial fluidJ Chromatogr B19987071-215160

24 

A Nakamura MN Nakashima M Wada K Nakashima Semi-micro column HPLC of three oxicam non-steroidal anti-Inflammatory drugs in human bloodBunseki Kagaku200554975560

25 

EA Taha NN Salama Abdel Fatt ah Lel-S. Stability-indicating chromatographic methods for the determination of some oxicamsJ AOAC Int200487236673

26 

RP Kiran SB Devanand VP Rane JN Sangshetti Stability-indicating LC method for analysis of lornoxicam in the dosage formChromatographia20096910015



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.